Logan G. Briggs, MD

Logan G. Briggs, MD, discusses the results of his upcoming paper on the efficacy of a range of interventions in improving outcomes for urologic cancer patients. Dr. Briggs and his co-authors examined over 400 randomized control trials (RCTs) that met criteria for design, population, review, and other factors, with 372 focusing on prostate cancer, 24 on bladder cancer, 20 on kidney cancer, and 14 on testicular cancer. 

The research team then examined the outcomes of nutrition, exercise, counseling, and pre-/rehabilitative interventions with the quality of life, physical/functional performance, cost-effectiveness, cardiometabolic profile, erectile function, and continence for each disease. Their analysis of these RCTs showed that 71% of interventions achieved positive results. 

With a goal of creating personalized, cost-effective pre-/rehabilitation programs for urologic cancer patients, Dr. Briggs suggests further work will need to be done in analyzing cost effectiveness, variance by race/ethnicity, and clinical significance of these findings. He also further discusses the significant amount of data from these RCTs showing the potential importance of these interventions for men with prostate cancer undergoing androgen deprivation therapy.